Yang, Wei
Lee, Ken-Wing http://orcid.org/0000-0003-0846-7521
Srivastava, Raghvendra M.
Kuo, Fengshen http://orcid.org/0000-0003-1797-2896
Krishna, Chirag
Chowell, Diego
Makarov, Vladimir
Hoen, Douglas
Dalin, Martin G.
Wexler, Leonard
Ghossein, Ronald
Katabi, Nora
Nadeem, Zaineb
Cohen, Marc A.
Tian, S. Ken
Robine, Nicolas http://orcid.org/0000-0001-5698-8183
Arora, Kanika
Geiger, Heather
Agius, Phaedra
Bouvier, Nancy
Huberman, Kety
Vanness, Katelynd
Havel, Jonathan J. http://orcid.org/0000-0003-0951-510X
Sims, Jennifer S.
Samstein, Robert M.
Mandal, Rajarsi
Tepe, Justin
Ganly, Ian
Ho, Alan L.
Riaz, Nadeem
Wong, Richard J.
Shukla, Neerav
Chan, Timothy A. http://orcid.org/0000-0002-9265-0283
Morris, Luc G. T. http://orcid.org/0000-0002-4417-2280
Article History
Received: 16 January 2019
Accepted: 22 March 2019
First Online: 22 April 2019
Competing interests
: K.-W.L. and J.S.S. are now full-time employees of Regeneron Pharmaceuticals. R. M. Srivastava received speaker fees and travel reimbursement from Innovent Biologics, Inc. A.L.H. receives research funding from Eli Lilly, Genentech, AstraZeneca, Bayer, Kura Oncology, Kotan Pharmaceuticals, Eisai, Bristol-Myers Squibb, Astellas Pharma, Novartis, Merck, Pfizer, Ayla Pharmaceuticals, Allos Therapuetics, Daiichi Sankyo, consulting fees from Bristol-Myers Squibb, Eisai, Genzyme, Merck, Novartis, Sun Pharma, Regeneron, TRM Oncology, Ayala Pharmaceuticals, AstraZeneca, Sanofi Aventis, and travel reimbursement from Janssen Oncology, Merck, Kura Oncology, Ignyta, Ayala Pharmacueticals. J.J.H’s spouse is a full-time employee of Regeneron Pharmaceuticals. R. M. Samstein, T.A.C. and L.G.T.M. are inventors on a provisional patent application (62/569,053) filed by Memorial Sloan Kettering (MSK) relating to the use of TMB in cancer immunotherapy. D.C. and T.A.C. are inventors on a PCT patent application (PCT/US2015/062208) filed by MSK relating to the use of TMB in cancer immunotherapy. MSK and the inventors may receive a share of commercialization revenue from license agreements relating to these patent applications. T.A.C. is a co-founder of Gritstone Oncology and holds equity. He acknowledges grant funding from Bristol-Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H, and Eisai, and has served as an advisor for Bristol-Myers Squibb, Illumina, Eisai and An2H. L.G.T.M. received consulting fees from Rakuten Aspyrian and speaker fees from Physician Educational Resources.